Understand the source comparison
Comparison of Neuroprotective Peptides in Parkinson's Research
Cerebrolysin Neurotrophic factor upregulation (BDNF, NGF, GDNF) + antioxidant enzyme activation Phase III completed UPDRS-III scores improved by 8.4 points vs 3.1 placebo in 4-week trials 30–50% reduction in dopaminergic cell loss in MPTP/6-OHDA rodent models
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- Neurotrophic factor upregulation (BDNF, NGF, GDNF) + antioxidant enzyme activation
- Phase III completed
- UPDRS-III scores improved by 8.4 points vs 3.1 placebo in 4-week trials
- 30–50% reduction in dopaminergic cell loss in MPTP/6-OHDA rodent models
- Most robust clinical data among peptide candidates; reproducible motor improvements in multiple RCTs but long-term neuroprotection unproven
- P21 (Cyclin-dependent kinase inhibitor peptide)
- Cell cycle arrest in post-mitotic neurons + anti-apoptotic signaling
- Preclinical only
- No human motor data available
- 40–60% striatal dopamine preservation in 6-OHDA rat models
- Promising preclinical profile but no human safety or efficacy data; mechanism targets apoptosis pathways distinct from neurotrophic support
- PACAP (Pituitary adenylate cyclase-activating polypeptide)
- cAMP/PKA pathway activation + mitochondrial stabilization
- Phase I completed
- No motor endpoint data in Parkinson's trials (tested in stroke)
- 35–45% tyrosine hydroxylase-positive cell preservation in MPTP mouse models
- Strong neuroprotective mechanism but clinical development stalled; blood-brain barrier penetration remains a delivery challenge
- Synthetic GDNF peptide mimetics
- Direct GDNF receptor (GFRα1) activation
- No human data
- 50–70% dopaminergic neuron survival in viral vector-lesioned primates
- Highest preclinical efficacy but no approved clinical candidates; delivery method (intracerebroventricular infusion) limits translation
- Semax (ACTH analog)
- Neurotrophic factor gene expression + monoamine modulation
- Phase II (Russia)
- Modest UPDRS improvements (5–7 point reduction) in small open-label trials
- Limited data. One study showed 20–30% striatal dopamine sparing in hemiparkinsonian rats
- Weaker clinical evidence than cerebrolysin; most trials lack placebo controls and use non-standardized outcome measures
- The comparison highlights why cerebrolysin occupies a unique position in Parkinson's research. It's the only peptide-based neuroprotective agent with reproducible Phase III motor function data published in peer-reviewed journals. GDNF mimetics show stronger preclinical neuroprotection, but delivery barriers have prevented human trials. PACAP's mechanism is elegant, but clinical development hasn't advanced beyond stroke applications. Cerebrolysin's reproducibility across multiple independent trials. Not just efficacy in a single study. Is what separates it from experimental candidates.